Advances in antibody drug for cancer targeted therapy
10.3969/j.issn.1005-1678.2016.06.04
- VernacularTitle:肿瘤靶向治疗抗体药物的研究进展
- Author:
Rui CAO
;
Rongguang SHAO
;
Liang LI
- Publication Type:Journal Article
- Keywords:
anti-tumor;
monoclonal antibody;
molecular targeted therapy;
antibody-based drugs
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(6):15-18
- CountryChina
- Language:Chinese
-
Abstract:
With the recent understanding of cancer biology, physiopathology, and cancer genetics& genomics, new treatments and methodologies are constantly developed, including on the development and application of molecular targeted drugs for cancer therapy have been widespread concerned.Antibody-based drugs targeting over-expressed oncogenes or other functional proteins in cancer with its high specificity, less side-effects and significant clinical efficacy became rapidly the hot-spot of anti-tumor drug research.Currently, there are already more than 20 of anti-tumor antibody-based drugs approved for clinical application, and achieved remarkable results.This article summarizes the development and current situation of monoclonal antibody-based drug research for cancer therapy, as well as their anti-tumor mechanism of action.At the same time summarizes the new advances in cancer research in the field of monoclonal antibody drugs made,and its prospects as well as shortcomings were outlined.
